Yahoo! Finance: Top Stories

Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer

May 31, 2025 - 08:10
 0
Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer
Read More

Tags:

Previous Article

Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors

Next Article

Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System

Related Posts

DLA Piper appoints Matt Tweedie as CFO

DLA Piper appoints Matt Tweedie as CFO

May 28, 2025  0

M&S picks Coles executive Thinus Keeve to drive retail strategy

M&S picks Coles executive Thinus Keeve to drive retail ...

May 28, 2025  0

Grant Thornton names Rick Surett as new CFO

Grant Thornton names Rick Surett as new CFO

Jun 3, 2025  0